Gilead Sciences, Inc.
GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment ofā¦ read more
Healthcare
Drug ManufacturersāGeneral
33 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$127.51
Price+0.31%
$0.39
1Y
Price
Market Cap
$158.199b
Large
Price/Earnings 3y Avg5y Avg
15.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+59.0%
EBITDA Margin+39.3%
Net Profit Margin+51.0%
Free Cash Flow MarginRevenue
$29.086b
+1.2%
1y CAGR+2.2%
3y CAGR+1.6%
5y CAGREarnings
$8.110b
+1589.6%
1y CAGR+507.1%
3y CAGR+373.8%
5y CAGREPS
$6.45
+1597.4%
1y CAGR+509.8%
3y CAGR+375.8%
5y CAGRBook Value
$21.456b
$58.533b
Assets$37.077b
Liabilities$24.941b
DebtDebt to Assets
42.6%
1.8x
Debt to EBITDAFree Cash Flow
$9.162b
-11.1%
1y CAGR+5.6%
3y CAGR-1.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company